B-type Natriuretic Peptides for the Prediction of Cardiovascular Events in Patients with Stable Coronary Heart Disease: the Heart and Soul Study

Overview

Journal J Am Heart Assoc

Specialty Cardiology & Vascular Diseases

Date 2014 Jul 24

PMID 25053234

Citations 27

Authors

Rakesh K Mishra

Alexis L Beatty

Rajesh Jaganath

Mathilda Regan

Alan H B Wu

Mary A Whooley

Affiliations

Soon will be listed here.

Abstract

Background: Brain-type natriuretic peptide (BNP) and the amino-terminal fragment of its prohormone (NT-proBNP) are known predictors of cardiovascular outcomes in patients with coronary heart disease; however, the relative prognostic value of these 2 biomarkers for secondary events remains unclear.

Methods And Results: In 983 participants with stable coronary heart disease, we evaluated the association of BNP and NT-proBNP with time to hospitalization for heart failure, nonfatal myocardial infarction, stroke or transient ischemic attack, cardiovascular death, and combined major adverse cardiovascular events (MACE). During an average follow-up of 6.5±3.3 years, both BNP and NT-proBNP were associated with increased risk of MACE in a multivariable-adjusted model (hazard ratio per standard deviation of log BNP: 1.58; 95% CI: 1.32 to 1.89; hazard ratio per standard deviation of log NT-proBNP: 1.84; 95% CI: 1.52 to 2.24). When added to traditional risk factors, NT-proBNP predicted MACE better than BNP (C statistic: 0.76 versus 0.72, P<0.001). Similarly, the addition of NT-proBNP resulted in a greater net reclassification improvement for predicting MACE than the addition of BNP (65% for NT-proBNP, 56% for BNP).

Conclusions: Both BNP and NT-proBNP were significant predictors of MACE in stable coronary heart disease; however, NT-proBNP was superior to BNP for net risk reclassification for MACE.

Citing Articles

Heart failure biomarkers in revascularized patients with stable coronary heart disease as clinical outcome predictors.

Bosnjak I, Bedekovic D, Selthofer-Relatic K, Roguljic H, Mihaljevic I, Dukic D Front Cardiovasc Med. 2024; 11:1458120.

PMID: 39346100 PMC: 11428046. DOI: 10.3389/fcvm.2024.1458120.

Plasma B-type natriuretic peptide is independently associated with cardiovascular events and mortality in patients with chronic kidney disease.

Hayashida H, Haruyama N, Fukui A, Yoshitomi R, Fujisawa H, Nakayama M Sci Rep. 2024; 14(1):16542.

PMID: 39019977 PMC: 11255297. DOI: 10.1038/s41598-024-67529-1.

Universal Risk Prediction for Individuals With and Without Atherosclerotic Cardiovascular Disease.

Mok Y, Dardari Z, Sang Y, Hu X, Bancks M, Mathews L J Am Coll Cardiol. 2024; 83(5):562-573.

PMID: 38296400 PMC: 11702005. DOI: 10.1016/j.jacc.2023.11.028.

Impact of heart failure severity and major bleeding events after percutaneous coronary intervention on subsequent major adverse cardiac events.

Ikebe S, Ishii M, Otsuka Y, Nakamura T, Tsujita K, Matoba T Int J Cardiol Cardiovasc Risk Prev. 2023; 18:200193.

PMID: 37415925 PMC: 10320317. DOI: 10.1016/j.ijcrp.2023.200193.

Stress-Delta B-Type Natriuretic Peptide Does Not Exclude ACS in the ED.

Susman S, Bouffler A, Gordee A, Kuchibhatla M, Leahy J, Griffin S J Appl Lab Med. 2022; 7(5):1098-1107.

PMID: 35587711 PMC: 9939016. DOI: 10.1093/jalm/jfac027.

References

Luchner A, Hengstenberg C, Lowel H, Riegger G, Schunkert H, Holmer S . Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension. 2005; 46(1):118-23. DOI: 10.1161/01.HYP.0000170140.36633.8f. View

Schiller N, Shah P, Crawford M, DeMaria A, Devereux R, FEIGENBAUM H . Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989; 2(5):358-67. DOI: 10.1016/s0894-7317(89)80014-8. View

Luepker R, Apple F, Christenson R, Crow R, Fortmann S, Goff D . Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and.... Circulation. 2003; 108(20):2543-9. DOI: 10.1161/01.CIR.0000100560.46946.EA. View

Van Kimmenade R, Januzzi Jr J, Bakker J, Houben A, Rennenberg R, Kroon A . Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol. 2009; 53(10):884-90. DOI: 10.1016/j.jacc.2008.11.032. View

Sakai H, Tsutamoto T, Ishikawa C, Tanaka T, Fujii M, Yamamoto T . Direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP secretion and extent of coronary artery stenosis in patients with stable coronary artery disease. Circ J. 2007; 71(4):499-505. DOI: 10.1253/circj.71.499. View

Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R . N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005; 352(7):666-75. DOI: 10.1056/NEJMoa042330. View

Omland T, Richards A, Wergeland R, Vik-Mo H . B-type natriuretic peptide and long-term survival in patients with stable coronary artery disease. Am J Cardiol. 2004; 95(1):24-8. DOI: 10.1016/j.amjcard.2004.08.058. View

McKie P, Rodeheffer R, Cataliotti A, Martin F, Urban L, Mahoney D . Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension. 2006; 47(5):874-80. PMC: 2647805. DOI: 10.1161/01.HYP.0000216794.24161.8c. View

Bibbins-Domingo K, Gupta R, Na B, Wu A, Schiller N, Whooley M . N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA. 2007; 297(2):169-76. PMC: 2848442. DOI: 10.1001/jama.297.2.169. View

10.

Ndrepepa G, Braun S, Niemoller K, Mehilli J, von Beckerath N, Beckerath O . Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina. Circulation. 2005; 112(14):2102-7. DOI: 10.1161/CIRCULATIONAHA.105.550715. View

11.

Yeboah J, Folsom A, Burke G, Johnson C, Polak J, Post W . Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation. 2009; 120(6):502-9. PMC: 2740975. DOI: 10.1161/CIRCULATIONAHA.109.864801. View

12.

Omland T, Sabatine M, Jablonski K, Rice M, Hsia J, Wergeland R . Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol. 2007; 50(3):205-14. DOI: 10.1016/j.jacc.2007.03.038. View

13.

Stevens L, Coresh J, Schmid C, Feldman H, Froissart M, Kusek J . Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. 2008; 51(3):395-406. PMC: 2390827. DOI: 10.1053/j.ajkd.2007.11.018. View

14.

Pencina M, DAgostino Sr R, Steyerberg E . Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011; 30(1):11-21. PMC: 3341973. DOI: 10.1002/sim.4085. View

15.

Mueller T, Gegenhuber A, Poelz W, Haltmayer M . Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta. 2004; 341(1-2):41-8. DOI: 10.1016/j.cccn.2003.10.027. View

16.

Clerico A, Fontana M, Zyw L, Passino C, Emdin M . Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. Clin Chem. 2007; 53(5):813-22. DOI: 10.1373/clinchem.2006.075713. View

17.

Glaser R, Peacock W, Wu A, Muller R, Mockel M, Apple F . Placental growth factor and B-type natriuretic peptide as independent predictors of risk from a multibiomarker panel in suspected acute coronary syndrome (Acute Risk and Related Outcomes Assessed With Cardiac Biomarkers [ARROW]) study. Am J Cardiol. 2011; 107(6):821-6. DOI: 10.1016/j.amjcard.2010.11.003. View

18.

Pencina M, DAgostino R, Vasan R . Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med. 2010; 48(12):1703-11. PMC: 3155999. DOI: 10.1515/CCLM.2010.340. View

19.

Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M . Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994; 90(1):195-203. DOI: 10.1161/01.cir.90.1.195. View

20.

Scirica B, Sabatine M, Jarolim P, Murphy S, de Lemos J, Braunwald E . Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. Eur Heart J. 2010; 32(6):697-705. PMC: 6279197. DOI: 10.1093/eurheartj/ehq468. View